| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:31699096 | IVR | 1 - 2 mg/kg | 1 - 2 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 2 mg/kg | 1 - 2 mg/kg | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 2 mg/kg | 1 - 2 mg/kg | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Induce apoptosis of hepatocytes | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.